Results
Senores Pharmaceuticals Q2 & H1FY27 Investor Presentation
Senores Pharmaceuticals reported strong Q2FY27 revenue growth of 24.9% and H1FY27 growth of 30.0% driven by regulated markets.
EBITDA grew 38.3% in Q2FY27 and 58.2% in H1FY27 with margin expansion of
